-Horizon Therapeutics plc - Presentations at the 2023 EULAR European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjogren's syndrome

Press/Media

Period1 Jun 2023

Media coverage

2

Media coverage